Cargando…

Association between Cerebrospinal Fluid Soluble TREM2, Alzheimer’s Disease and Other Neurodegenerative Diseases

Background: Cerebrospinal fluid (CSF) soluble triggering receptor expressed on myeloid cells 2 (sTREM2) is a potential biomarker and therapy target for neurodegenerative diseases (NDDs). The purpose of this meta-analysis was to investigate the association between CSF sTREM2 level and NDDs, and to re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Wenchuan, Zhou, Yutong, Li, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219449/ https://www.ncbi.nlm.nih.gov/pubmed/37240695 http://dx.doi.org/10.3390/jcm12103589

Ejemplares similares

Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease
por: Henjum, Kristi, et al.
Publicado: (2016)

Association of rs2062323 in the TREM1 gene with Alzheimer's disease and cerebrospinal fluid‐soluble TREM2
por: Wang, Zuo‐Teng, et al.
Publicado: (2023)

Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease
por: Heslegrave, Amanda, et al.
Publicado: (2016)

Genome-Wide Association Studies for Cerebrospinal Fluid Soluble TREM2 in Alzheimer’s Disease
por: Liu, Changan, et al.
Publicado: (2019)

A high cerebrospinal fluid soluble TREM2 level is associated with slow clinical progression of Alzheimer's disease
por: Edwin, Trine Holt, et al.
Publicado: (2020)

Cerebrospinal fluid sTREM2 in Alzheimer’s disease: comparisons between clinical presentation and AT classification
por: Knapskog, Anne-Brita, et al.
Publicado: (2020)

The relationship of soluble TREM2 to other biomarkers of sporadic Alzheimer’s disease
por: Park, So-Hee, et al.
Publicado: (2021)

Cerebrospinal fluid neurogranin and TREM2 in Huntington’s disease
por: Byrne, Lauren M., et al.
Publicado: (2018)

Soluble TREM2 Concentrations in the Cerebrospinal Fluid Correlate with the Severity of Neurofibrillary Degeneration, Cognitive Impairment, and Inflammasome Activation in Alzheimer’s Disease
por: Španić Popovački, Ena, et al.
Publicado: (2023)

TREM2 in Neurodegenerative Diseases
por: Jay, Taylor R., et al.
Publicado: (2017)

Cerebrospinal fluid sampling for research of Alzheimer’s disease and other neurodegenerative diseases when lumbar punctures are performed by anaesthetists
por: Atkins, Kelly J, et al.
Publicado: (2022)

Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup
por: Woollacott, Ione O. C., et al.
Publicado: (2018)

TREM2 ectodomain and its soluble form in Alzheimer’s disease
por: Yang, Jiaolong, et al.
Publicado: (2020)

Does Soluble TREM2 Protect Against Alzheimer's Disease?
por: Brown, Guy C., et al.
Publicado: (2022)

The Emerging Roles and Therapeutic Potential of Soluble TREM2 in Alzheimer’s Disease
por: Zhong, Li, et al.
Publicado: (2019)

Soluble Megalin is Reduced in Cerebrospinal Fluid Samples of Alzheimer’s Disease Patients
por: Spuch, Carlos, et al.
Publicado: (2015)

TREM2 in CNS homeostasis and neurodegenerative disease
por: Painter, Meghan M., et al.
Publicado: (2015)

The Role of TREM2 in Alzheimer’s Disease and Other Neurological Disorders
por: Yaghmoor, Faris, et al.
Publicado: (2014)

Age Matching Is Essential for the Study of Cerebrospinal Fluid sTREM2 Levels and Alzheimer’s Disease Risk: A Meta-Analysis
por: Hu, Shimin, et al.
Publicado: (2021)

Summary of cerebrospinal fluid routine parameters in neurodegenerative diseases
por: Jesse, Sarah, et al.
Publicado: (2010)

Metabolites and Biomarker Compounds of Neurodegenerative Diseases in Cerebrospinal Fluid
por: Wakamatsu, Keiji, et al.
Publicado: (2022)

Soluble TREM2 levels associate with conversion from mild cognitive impairment to Alzheimer’s disease
por: Zhao, Aonan, et al.
Publicado: (2022)

Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study
por: Morenas-Rodríguez, Estrella, et al.
Publicado: (2022)

TREM2 deficiency in microglia accelerates photoreceptor cell death and immune cell infiltration following retinal detachment
por: Zhou, Wenchuan, et al.
Publicado: (2023)

The Role of Cerebrospinal Fluid Biomarkers in Dementia and Other Related Neurodegenerative Disorders
por: Paraskevas, George P.
Publicado: (2022)

sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers
por: Suárez‐Calvet, Marc, et al.
Publicado: (2016)

TREM2-Dependent Effects on Microglia in Alzheimer’s Disease
por: Zhou, Yingyue, et al.
Publicado: (2018)

Proteinase-activated receptor 2 and disease biomarkers in cerebrospinal fluid in cases with autopsy-confirmed prion diseases and other neurodegenerative diseases
por: Rohan, Zdenek, et al.
Publicado: (2015)

Postoperative changes in cognition and cerebrospinal fluid neurodegenerative disease biomarkers
por: Berger, Miles, et al.
Publicado: (2022)

Soluble TREM2 ameliorates tau phosphorylation and cognitive deficits through activating transgelin-2 in Alzheimer’s disease
por: Zhang, Xingyu, et al.
Publicado: (2023)

Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer’s disease model
por: Zhong, Li, et al.
Publicado: (2019)

TREM2 Protein Expression Changes Correlate with Alzheimer's Disease Neurodegenerative Pathologies in Post‐Mortem Temporal Cortices
por: Lue, Lih‐Fen, et al.
Publicado: (2014)

Metabolite Profiling of Alzheimer's Disease Cerebrospinal Fluid
por: Czech, Christian, et al.
Publicado: (2012)

Analysis of the Cerebrospinal Fluid Proteome in Alzheimer's Disease
por: Khoonsari, Payam Emami, et al.
Publicado: (2016)

Alzheimer disease pathology and the cerebrospinal fluid proteome
por: Dayon, Loïc, et al.
Publicado: (2018)

Tau oligomers in cerebrospinal fluid in Alzheimer's disease
por: Sengupta, Urmi, et al.
Publicado: (2017)

Melatonin in Alzheimer's disease and other neurodegenerative disorders
por: Srinivasan, V, et al.
Publicado: (2006)

Soluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimer’s disease progression
por: De, Suman, et al.
Publicado: (2019)

Associations of cerebrospinal fluid amyloidogenic nanoplaques with cytokines in Alzheimer’s disease
por: Aksnes, Mari, et al.
Publicado: (2021)

Neurofilament light oligomers in neurodegenerative diseases: quantification by homogeneous immunoassay in cerebrospinal fluid
por: Meda, Francisco J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_orlt566objsq4c2pe7bbua6ont